Overcoming mutation-based resistance to antiandrogens with rational drug design
The second-generation antiandrogen enzalutamide was recently approved for patients with castration-resistant prostate cancer. Despite its success, the duration of response is often limited. For previous antiandrogens, one mechanism of resistance is mutation of the androgen receptor (AR). To prospect...
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
eLife Sciences Publications Ltd
2013-04-01
|
| Serie: | eLife |
| Soggetti: | |
| Accesso online: | https://elifesciences.org/articles/00499 |